Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Toxic Epidermal Necrolysis (Lyell) Syndrome”

6 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 6 of 6 results

Large-scale testing (Phase 3)UnknownNCT04651439
What this trial is testing

Severe Bullous Drug Eruption and Filgrastim

Who this might be right for
Rare DiseasesToxic Epidermal Necrolyses
Hospices Civils de Lyon 42
Testing effectiveness (Phase 2)WithdrawnNCT02126020
What this trial is testing

Topical Infliximab in Autoimmune Eyes With Keratoprosthesis

Who this might be right for
Stevens-Johnson SyndromeToxic Epidermal Necrolysis (Lyell) SyndromeMucous Membrane Pemphigoid
James Chodosh, MD, MPH
Not applicableLooking for participantsNCT03659227
What this trial is testing

Drug Reactions Sampling (COLLECTIONTOXIDERMIES)

Who this might be right for
Stevens-Johnson SyndromeLyell SyndromeDrug Reactions+5 more
Assistance Publique - Hôpitaux de Paris 500
Testing effectiveness (Phase 2)Looking for participantsNCT04711200
What this trial is testing

LYell SYndrome MEsenchymal Stromal Cells Treatment

Who this might be right for
Epidermal NecrolysisLyell SyndromeToxic Epidermal Necrolysis+3 more
Assistance Publique - Hôpitaux de Paris 15
Testing effectiveness (Phase 2)UnknownNCT05520086
What this trial is testing

Clinical Trial to Evaluate Safety and Efficacy of Cell Therapy in Patients With Cicatricial Conjuntivitis.

Who this might be right for
Chronic ConjunctivitisStevens-Johnson SyndromeLyell Syndrome+1 more
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz 20
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07110662
What this trial is testing

New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies.

Who this might be right for
Toxic Epidermal NecrolysisImmunotherapyCutaneous Adverse Drug Reactions (CADR)
Hospices Civils de Lyon 9